What is Intermediates in Pharmaceutical Industry?

Comments · 56 Views

In the pharmaceutical industry, intermediates, also known as pharmaceutical intermediates (PIs), are chemical compounds that undergo further modification or processing to become active pharmaceutical ingredients (APIs). APIs are the pharmacologically active components of drugs that are res

 

Classification of Intermediates

Intermediates can be categorized into two main types:

1. Synthetic intermediates: These are compounds that are chemically synthesized from raw materials through a series of reactions. Synthetic intermediates are often complex molecules that require multiple steps to produce.

2. Naturally derived intermediates: These are compounds that are extracted from natural sources, such as plants or microorganisms. Naturally derived intermediates can be difficult to obtain and may require specialized extraction techniques.

The production of intermediates is a crucial step in the pharmaceutical manufacturing process. Intermediates must meet strict quality standards to ensure the safety and efficacy of the final API.

Key Characteristics of Pharmaceutical Intermediates

Here are some of the key characteristics of pharmaceutical intermediates:

1. Purity: Intermediates must be of high purity to avoid the introduction of impurities into the final API.

2. Stability: Intermediates must be stable during storage and transportation to prevent degradation.

3. Scalability: The production of intermediates must be scalable to meet the demand for the final API.

4. Cost-effectiveness: The production of intermediates must be cost-effective to make the final API affordable.

The pharmaceutical intermediates market is a global industry with a value of over $100 billion. The market is driven by the growing demand for new drugs, the increasing complexity of drug development, and the need for high-quality intermediates.

Here are some of the leading pharmaceutical intermediates companies:

  • Evonik Industries AG
  • BASF SE
  • Merck KGaA
  • Lonza Group AG
  • DSM
Comments